AETNA BE	TTER HEALTH®			aetna™
Coverage	Policy/Guideline			
Name:	Lyrica CR		Page:	1 of 2
Effective Date: 2/3/2023			Last Review Date:	
Applies to:	□Illinois	□Florida	🗆 Florida Kids	
	□New Jersey	⊠Maryland	□Michigan	
	🗆 Pennsylvania Kids	□Virginia		

# Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Lyrica CR under the patient's prescription drug benefit.

# **Description:**

Lyrica CR is indicated for the management of:

- Neuropathic pain associated with diabetic peripheral neuropathy
- Postherpetic neuralgia

Efficacy of Lyrica CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.

# **Applicable Drug List:**

Non-Formulary: Lyrica CR

## **Policy/Guideline:**

The requested drug will be covered with prior authorization when the following criteria are met:

- Lyrica CR (pregabalin extended-release) is being prescribed for the management of
  - o postherpetic neuralgia OR
  - o neuropathic pain associated with diabetic peripheral neuropathy

## **Approval Duration and Quantity Restrictions:**


## Approval: 12 months

Quantity Level Limit: Reference Formulary for drug specific quanitity level limits

## **References:**

1. Cymbalta [package insert]. Indianapolis, IN: Lilly USA, LLC; September 2021.

- 2. Lyrica [package insert]. New York, NY: Parke-Davis; June 2020.
- 3. Lyrica CR [package insert]. New York, NY: Parke-Davis; June 2020.
- 4. Neurontin [package insert]. New York, NY: Parke-Davis Division of Pfizer Inc; December 2020.



5. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: UpToDate, Inc.; 2022; Accessed April 18, 2022.

6. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com. Accessed April 18, 2022.

7. American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Suppl. 1): S185-S194.

8. Pop-Busui R, Boulton A, Feldman E, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40:136–154.

9. Price R, Smith D, Franklin D et. al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Report of the AAN Guideline Subcommittee. Neurology 2022; 98:31-43.

10. NCCN Guidelines. Version 1.2022 Adult Cancer Pain. Available at

http://www.nccn.org/professionals/physician\_gls/pdf/pain.pdf. Accessed April 2022.

11. Fisher RS, Cross JH, French JA, et al. Operational Classification of seizure types by the

International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-530.